This is a Class I recall where 56 serious injuries have been reported. If you use one of Dexcom's continuous glucose monitoring systems, here's what you need to know. Taylor Leamey wrote about all ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the continuous glucose monitoring (CGM) market. A strong third-quarter 2025 performance and a series ...

DexCom announced that Chairman and CEO Kevin R. Sayer has taken a temporary medical leave as of September 14, 2025, with President and COO Jacob S. Leach appointed interim CEO and Mark Foletta as ...

Dexcom builds on its history of first-in-market innovations with the launch of its new groundbreaking GenAI platform Dexcom GenAI-enabled technology will leverage Google Cloud’s Vertex AI platform and ...

DexCom's returns over the past decade have been solid, but not quite on par with the market's. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the ...

Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...

As the United States approaches 2026, key structural shifts in retirement and healthcare financing are poised to affect how ...

Shares of medical device company DexCom (NASDAQ:DXCM) fell 7.4% in the morning session after a short-seller report from Hunterbrook Capital alleged issues with the company's G7 glucose monitoring ...

We think that DexCom stock (NASDAQ NDAQ: DXCM) is currently a better pick than Insulet stock (NASDAQ: PODD), given DexCom’s DXCM better prospects and comparatively lower valuation. DXCM stock trades ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...